SavedAdd your journal

Journals / Recent Trends in Pharmacology / 2026 / Volume: 4 Issue: 1

A Structure-Based in Silico Study Proposes Glycophorin-E as a Dual Target for Parkinson’s Disease and Alcohol Use Disorder Modulated by Oleuropein (OLE) Glycophorin-E: A Dual Target for PD/AUD via Oleuropein

Azizeh Shadidizaji(ATATURK UNIVERSITY)0009-0007-5573-1360
Kağan Tolga Cinisli(ATATURK UNIVERSITY)0000-0003-3909-9637
Dilanur Ateş(ATATURK UNIVERSITY)0009-0004-5182-1703
Irmak Ferah Okkay(Atatürk Üniversitesi)0000-0001-8836-9547
Pages
—
Publication Date
2026-01-15
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Importantly, Tyr39 plays a dual role by also forming a stabilizing salt bridge, adding notable ionic interaction energy that helps stabilize the overall complex.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Parkinson’s disease (PD) and alcohol use disorder (AUD) have different clinical profiles, but they may share certain molecular weaknesses.
📊
Key Findings & Data:Results: The analysis showed that OLE has a stable and energetically favorable binding position in a proposed active site of GYPE, with a binding strength of -5.3 kcal/mol.
💡
Conclusion & Impact:Importantly, Tyr39 plays a dual role by also forming a stabilizing salt bridge, adding notable ionic interaction energy that helps stabilize the overall complex.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Glycophorin-E · Oleuropein · Alcohol Use Disorder

Abstract

Objective: Parkinson’s disease (PD) and alcohol use disorder (AUD) have different clinical profiles, but they may share certain molecular weaknesses. This computer-based study explores the new idea that Glycophorin-E (GYPE) could be a common target for both conditions, with the natural compound oleuropein (OLE) as a possible modulator. Methods: Using structure-based computational methods, we conducted molecular docking and interaction analysis to examine how OLE binds to a modeled GYPE structure. Results: The analysis showed that OLE has a stable and energetically favorable binding position in a proposed active site of GYPE, with a binding strength of -5.3 kcal/mol. The complex’s stability comes from a mix of specific intermolecular forces, including important hydrophobic interactions with Val35 and Tyr39, along with essential hydrogen bonds with Ser30, Thr36, Tyr39, and Gln43. Importantly, Tyr39 plays a dual role by also forming a stabilizing salt bridge, adding notable ionic interaction energy that helps stabilize the overall complex. These findings present the first computer-based evidence for strong and specific binding of OLE to GYPE. Conclusion: We suggest that this interaction could explain how OLE shows neuroprotective and anti-addictive effects by influencing GYPE-related pathways. However, this study has limitations since it is a computer-based analysis. Also, because Glycophorin E is a protein with low biological expression, further in vivo and in vitro studies are needed to confirm its potential effects in the body.

🔖

Cite This Article

Shadidizaji, A., Cinisli, K. T., Ateş, D., Okkay, I. F. (2026). A Structure-Based in Silico Study Proposes Glycophorin-E as a Dual Target for Parkinson’s Disease and Alcohol Use Disorder Modulated by Oleuropein (OLE) Glycophorin-E: A Dual Target for PD/AUD via Oleuropein. Recent Trends in Pharmacology, Volume: 4 Issue: 1. https://doi.org/10.62425/rtpharma.1836939

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (35)

  1. Alfaidi, M., Barker, RA., & Kuan, WL. (2025). An update on immune-based alpha-synuclein trials in Parkinson’s disease. Journal of Neurology, 272(1), 1–9. https://doi.org/10.1007/S00415-024-12770
  2. Bembnowska, M., & Jośko-Ochojska, J. (2015). What causes depression in adults? Polish Journal of Public Health, 125(2), 116–120. https://doi.org/10.1515/PJPH-2015-0037
  3. Bulle, S., Reddy, VD., Padmavathi, P., Maturu, P., Puvvada, PK., & Nallanchakravarthula, V. (2016). Association between alcohol-induced erythrocyte membrane alterations and hemolysis in chronic alcoholics. Journal of Clinical Biochemistry and Nutrition, 60(1), 63. https://doi.org/10.3164/JCBN.16-16
  4. Butt, MS., Tariq, U., Iahtisham-Ul-Haq, Naz, A., & Rizwan, M. (2021). Neuroprotective effects of oleuropein: Recent developments and contemporary research. Journal of Food Biochemistry, 45(12), e13967. https://doi.org/10.1111/JFBC.13967
  5. Cahill, CM., Aleyadeh, R., Gao, J., Wang, C., & Rogers, J. T. (2020). Alpha-Synuclein in Alcohol Use Disorder, Connections with Parkinson’s Disease and Potential Therapeutic Role of 5’ Untranslated Region-Directed Small Molecules. Biomolecules 10(10), 1–19. https://doi.org/10.3390/BIOM10101465
  6. Cole, TA., Zhao, H., Collier, TJ., Sandoval, I., Sortwell, CE., Steece-Collier, K., Daley, BF., Booms, A., Lipton, J., Welch, M., Berman, M., Jandreski, L., Graham, D., Weihofen, A., Celano, S., Schulz, E., Cole-Strauss, A., Luna, E., Quach, D., … Paumier, K. L. (2021). α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease. JCI Insight, 6(5), e135633. https://doi.org/10.1172/JCI.INSIGHT
  7. Collins, LM., Toulouse, A., Connor, TJ., & Nolan, YM. (2012). Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology, 62(7), 2154–2168. https://doi.org/10.1016/j.neuropharm
  8. Commenges, D., Scotet, V., Renaud, S., Jacqmin-Gadda, H., Barberger-Gateau, P., & Dartigues, J. F. (2000). Intake of flavonoids and risk of dementia. European Journal of Epidemiology, 16(4), 357–363. https://doi.org/10.1023/A:1007614613771/METRICS
  9. Crews, F., Nixon, K., Kim, D., Joseph, J., Shukitt-Hale, B., Qin, L., & Zou, J. (2006). BHT blocks NF-κB activation and ethanol-induced brain damage. Alcoholism: Clinical and Experimental Research, 30(11), 1938–1949. https://doi.org/10.1111/J.1530-0277.2006.00239
  10. Gaetano, G., Costanzo, S., Di Castelnuovo, A., Badimon, L., Bejko, D., Alkerwi, A., Chiva-Blanch, G., Estruch, R., La Vecchia, C., Panico, S., Pounis, G., Sofi, F., Stranges, S., Trevisan, M., Ursini, F., Cerletti, C., Donati, M. B., & Iacoviello, L. (2016). Effects of moderate beer consumption on health and disease: A consensus document. Nutrition, Metabolism and Cardiovascular Diseases, 26(6), 443–467. https://doi.org/10.1016/J.NUMECD
  11. Eriksson, AK., Löfving, S., Callaghan, RC., & Allebeck, P. (2013). Alcohol use disorders and risk of Parkinson’s disease: findings from a Swedish national cohort study 1972–2008. BMC Neurology, 13(1), 190. https://doi.org/10.1186/1471-2377-13-190
  12. Genc, N., Yildiz, I., Chaoui, R., Erenler, R., Temiz, C., & Elmastas, M. (2020). Biosynthesis, characterization and antioxidant activity of oleuropein-mediated silver nanoparticles. Inorganic and Nano-Metal Chemistry, 1–9. https://doi.org/10.1080/24701556.2020.1792495
  13. Hamelink, C., Hampson, A., Wink, DA., Eiden, LE., & Eskay, RL. (2005). Comparison of Cannabidiol, Antioxidants, and Diuretics in Reversing Binge Ethanol-Induced Neurotoxicity. The Journal of Pharmacology and Experimental Therapeutics, 314(2), 780–788. https://doi.org/10.1124/JPET.105.085779
  14. Janahmadi, Z., Nekooeian, A A., Moaref, AR., & Emamghoreishi, M. (2017). Oleuropein attenuates the progression of heart failure in rats by antioxidant and antiinflammatory effects. Naunyn-Schmiedeberg’s Archives of Pharmacology, 390(3), 245–252. https://doi.org/10.1007/S00210-016-1323-6
  15. Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery, and Psychiatry, 79(4), 368–376. https://doi.org/10.1136/JNNP.2007.131045
  16. Kamiloğlu, NN., Yıldız, B., Merhan, O., Öğün, M., Güven, A., Erkılıç, EE., Mecit, T., Şahin, P., & Hastürk, H. (2019). Effects of Oleuropein on Nitric Oxide, Glutathione, Malondialdehyde Levels and Glutathione Peroxidase Activities in Various Tissues of Streptozotocin-Induced Diabetic Rats Treated with Metformin and Insulin. Turkiye Klinikleri Journal of Veterinary Sciences, 10(1), 1–10. https://doi.org/10.5336/VETSCI.2018-63762
  17. Karabag-Coban, F., Hazman, O., Bozkurt, MF., & Ince, S. (2017). Antioxidant Status and Anti-inflammatory Effects of Oleuropein in Streptozotocin-induced Diabetic Nephropathy in Rats. European Journal of Medicinal Plants, 18(2), 1–10. https://doi.org/10.9734/EJMP/2017/31953
  18. Khalil, A. A., Rahman, M. M., Rauf, A., Islam, M. R., Manna, S. J., Khan, A. A., Ullah, S., Akhtar, M. N., Aljohani, A. S. M., Abdulmonem, W. Al, & Simal-Gandara, J. (2024). Oleuropein: Chemistry, extraction techniques and nutraceutical perspectives-An update. Critical Reviews in Food Science and Nutrition, 64(27), 9933–9954. https://doi.org/10.1080/10408398.2023.2218495
  19. Liu, R., Guo, X., Park, Y., Wang, J., Huang, X., Hollenbeck, A., Blair, A., & Chen, H. (2013). Alcohol Consumption, Types of Alcohol, and Parkinson’s Disease. PLOS ONE, 8(6), e66452. https://doi.org/10.1371/JOURNAL.PONE
  20. Malliou, F., Andreadou, I., Gonzalez, F.J., Lazou, A., Xepapadaki, E., Vallianou, I., Lambrinidis, G., Mikros, E., Marselos, M., Skaltsounis, AL., & Konstandi, M. (2018). The olive constituent oleuropein, as a PPARα agonist, markedly reduces serum triglycerides. The Journal of Nutritional Biochemistry, 59, 17–28. https://doi.org/10.1016/J.JNUTBIO
  21. Marras, C., Canning, CG., & Goldman, SM. (2019). Environment, lifestyle, and Parkinson’s disease: Implications for prevention in the next decade. Movement Disorders: Official Journal of the Movement Disorder Society, 34(6), 801–811. https://doi.org/10.1002/MDS.27720
  22. Morena, D., Manta, AM., Santurro, A., Scopetti, M., Turillazzi, E., & Fineschi, V. (2025). Bloody Evidence: The Validity of Glycophorin A in the Determination of Wound Vitality—A Systematic Review of the Literature. International Journal of Molecular Sciences, 26(11), 5308. https://doi.org/10.3390/IJMS26115308/S1
  23. Obernier, JA., Bouldin, TW., & Crews, FT. (2002). Binge ethanol exposure in adult rats causes necrotic cell death. Alcoholism: Clinical and Experimental Research, 26(4), 547–557. https://doi.org/10.1111/J.1530-0277.2002
  24. Orio, L., Alen, F., Pavón, F.J., Serrano, A., & García-Bueno, B. (2019). Oleoylethanolamide, neuroinflammation, and alcohol abuse. Frontiers in Molecular Neuroscience, 11, 427528. https://doi.org/10.3389/FNMOL
  25. Özcan, MM., & Matthäus, B. (2017). A review: benefit and bioactive properties of olive (Olea europaea L.) leaves. European Food Research and Technology, 243(1), 89–99. https://doi.org/10.1007/S00217-016-2726-9
  26. Park, JS., Ahmad, R., Choe, K., Kang, M. H., Park, T. J., & Kim, M. O. (2023). Immunization Effects of a Novel α-Synuclein-Based Peptide Epitope Vaccine in Parkinson’s Disease-Associated Pathology. Vaccines, 11(12), 1820. https://doi.org/10.3390/VACCINES11121820/S1
  27. Peng, B., Yang, Q., Joshi, RB., Liu, Y., Akbar, M., Song, B-J., Zhou, S., & Wang, X. (2020). Role of Alcohol Drinking in Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 21(7). https://doi.org/10.3390/IJMS21072316
  28. Przychodzen, P., Wyszkowska, R., Gorzynik-Debicka, M., Kostrzewa, T., Kuban-Jankowska, A., & Gorska-Ponikowska, M. (2019). Anticancer Potential of Oleuropein, the Polyphenol of Olive Oil, With 2-Methoxyestradiol, Separately or in Combination, in Human Osteosarcoma Cells. Anticancer Research, 39(3), 1243–1251. https://doi.org/10.21873/ANTICANRES
  29. Rahuel, C., Elouet, J. F., & Cartron, J. P. (1994). Post-transcriptional regulation of the cell surface expression of glycophorins A, B, and E. Journal of Biological Chemistry, 269(52), 32752–32758. https://doi.org/10.1016/S0021-9258(20)30055-7
  30. Santini, SJ., Porcu, C., Tarantino, G., Amicarelli, F., & Balsano, C. (2020). Oleuropein overrides liver damage in steatotic mice. Journal of Functional Foods, 65, 103756. https://doi.org/10.1016/J.JFF.2019.103756
  31. Tajuddin, N., Moon, K. H., Marshall, S. A., Nixon, K., Neafsey, E. J., Kim, H. Y., & Collins, M. A. (2014). Neuroinflammation and Neurodegeneration in Adult Rat Brain from Binge Ethanol Exposure: Abrogation by Docosahexaenoic Acid. Plos One, 9(7), e101223. https://doi.org/10.1371/JOURNAL.PONE
  32. Vallés, S. L., Blanco, A. M., Pascual, M., & Guerri, C. (2004). Chronic ethanol treatment enhances inflammatory mediators and cell death in the brain and in astrocytes. Brain Pathology, 14(4), 365–371. https://doi.org/10.1111/J.1750-3639.2004
  33. Yang, Q., Luo, C., Zhang, X., Liu, Y., Wang, Z., Cacciamani, P., Shi, J., Cui, Y., Wang, C., Sinha, B., Peng, B., Tong, G., Das, G., Shah, E., Gao, Y., Li, W., Tu, Y., Qian, D., Shah, K., … Wang, X. (2020). Tartary buckwheat extract alleviates alcohol-induced acute and chronic liver injuries through the inhibition of oxidative stress and mitochondrial cell death pathway. American Journal of Translational Research, 12(1), 70. https://pmc.ncbi.nlm.nih.gov/articles/PMC7013218/
  34. Zhao, Q., Bai, Y., Li, C., Yang, K., Wei, W., Li, Z., Pan, L., Li, X., & Zhang, X. (2017). Oleuropein protects cardiomyocyte against apoptosis via activating the reperfusion injury salvage kinase pathway in vitro. Evidence-Based Complementary and Alternative Medicine, 2017. https://doi.org/10.1155/2017/2109018
  35. Marras, C., Canning, CG., & Goldman, SM. (2019). Environment, lifestyle, and Parkinson’s disease: Implications for prevention in the next decade. Movement Disorders: Official Journal of the Movement Disorder Society, 34(6), 801–811. https://doi.org/10.1002/MDS.27720